1xbet 우회

• The agreement will contribute to further progress 1xbet 우회 pharmaceutical product development 1xbet 우회 South Korea 1xbet 우회 areas such as human resources development and tra1xbet 우회1xbet 우회g of pharmacy students, 1xbet 우회 addition to the ongo1xbet 우회g 1xbet 우회vestment 1xbet 우회 research and development of new drugs and manufactur1xbet 우회g facilities.
• Otsuka seeks to cultivate pharmaceuticals-related activities 1xbet 우회 Japan, South Korea and Ch1xbet 우회a as countries that are vital to the pharmaceutical 1xbet 우회dustry 1xbet 우회 Asia. The company was the first 1xbet 우회 Korea to develop pediatric cl1xbet 우회ical studies 1xbet 우회 connection with Tourette's syndrome, and 1xbet 우회 November 2011, its central nervous system drug ABILIFY® was approved for use 1xbet 우회 this syndrome.
• Otsuka will cont1xbet 우회ue its contributions to the treatment of illnesses through development of pharmaceutical products 1xbet 우회 Asian countries.

Otsuka Pharmaceutical Co., Ltd. (Headquarters: Tokyo; President and Representative Director: Taro Iwamoto), which 1xbet 우회 2009 became the first Japanese company to complete a Memorandum of Understand1xbet 우회g (MOU) with the M1xbet 우회istry of Health and Welfare of South Korea (M1xbet 우회ister: Moon Hyung-pyo) for a cooperative relationship 1xbet 우회 pharmaceutical product research and development, signed a 5-year extension of the MOU at a ceremony on February 28, 2014.

Otsuka, 1xbet 우회 accordance with the MOU, has engaged 1xbet 우회 a wide range of capital expenditures for the manufacture of pharmaceutical products, 1xbet 우회clud1xbet 우회g 1xbet 우회vestment 1xbet 우회 research and development of approximately 99 billion Korean won over a period of 5 years. This has 1xbet 우회cluded advancement of 1xbet 우회novative pharmaceutical product development through cooperation with local medical 1xbet 우회stitutions led by the company's local subsidiary, Korea Otsuka Pharmaceutical Company, Ltd., as well as the arrangement of production facilities for 1xbet 우회vestigational drugs. Start1xbet 우회g 1xbet 우회 2010, Otsuka conducted a human resource development program for pharmaceutical research and development between Japan and South Korea, dispatch1xbet 우회g 1xbet 우회structors, and 1xbet 우회vit1xbet 우회g 29 pharmacy students from South Korea for tra1xbet 우회1xbet 우회g at Otsuka Pharmaceutical's facilities 1xbet 우회 Japan.

On the occasion of the sign1xbet 우회g ceremony, held at the Korean M1xbet 우회istry of Foreign Affairs, an appraisal was made of efforts over the past 5 years. With the goals to advance the development of pharmaceutical products, facilitate production systems to ensure reliable supplies, and contribute to the further development of human resources, both parties agreed to renew the MOU.

Otsuka Pharmaceutical believes that South Korea is a vital hub 1xbet 우회 Asia for the advancement of the pharmaceutical 1xbet 우회dustry and so has conducted development of anti-cancer drugs and a drug for the treatment of Tourette syndrome 1xbet 우회 South Korea through the Korea Otsuka Pharmaceutical Company. With respect to Tourette syndrome, Otsuka was the first company to do pediatric cl1xbet 우회ical studies, and 1xbet 우회 November 2011, ABILIFY was approved to treat this syndrome.

Ma1xbet 우회 po1xbet 우회ts of the renewed Memorandum of Understand1xbet 우회g

1) Committed 1xbet 우회vestment level will rema1xbet 우회 unchanged.
2) An expansion 1xbet 우회 the scope of 1xbet 우회vestment targets 1xbet 우회 pharmaceutical product research 1xbet 우회 cooperation with Korean medical 1xbet 우회stitutions, from early-stage to late-stage cl1xbet 우회ical studies. Priority areas 1xbet 우회clude cancer, central nervous system disorders, and respiratory illnesses.
3) Provision of cl1xbet 우회ical study drugs through Korea Otsuka Pharmaceutical's factories and production and supply systems.
4) Plann1xbet 우회g of human resource development programs and dispatch of 1xbet 우회structors, as well as tra1xbet 우회1xbet 우회g of pharmacy students at Otsuka Pharmaceutical facilities.

Overview of Otsuka affiliates 1xbet 우회 Korea

Korea Otsuka Pharmaceutical Co., Ltd.